We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the U.S., the federal government said it no longer has to control the distribution process because there is a sufficient supply to treat COVID-19 patients. Read More
The patch has “shown the potential to transform vaccine delivery with lower dose requirements, enabling more patient-doses to be manufactured more quickly from limited vaccine supply,” the company said. Read More
Early identification of patients at risk will “enable physicians to more aggressively monitor these patients in a controlled environment and provide earlier treatment,” the company said. Read More
The test does not require RNA extraction reagents for capturing and concentrating viral nucleic acid, improving testing efficiency and decreasing reliance on testing supplies, LabCorp said. Read More
The European Medicines Agency’s (EMA) safety committee has begun a review of acute kidney injuries reported in some COVID-19 patients being treated with Gilead Sciences’ remdesivir. Read More
New guidance from the FDA that would set tougher conditions for COVID-19 vaccine Emergency Use Authorizations (EUAs) remains under White House review, and it is unclear when — or if — it may be released. Read More
Gilead Sciences has resumed direct distribution to hospitals of its antiviral drug remdesivir, after HHS decided that the federal government no longer has to control the process because there is a sufficient supply to treat COVID-19 patients. Read More
Pfizer will not allow political arm-twisting to speed up or delay its COVID-19 vaccine candidate trials, the company’s CEO Albert Bourla stressed in an open letter last week. Read More
President Trump is being treated with dexamethasone, remdesivir and Regeneron Pharmaceuticals’ investigational antibody cocktail in his battle against COVID-19, following his announcement Friday that he and the first lady had tested positive for the coronavirus. Read More
Pending FDA approval or authorization, the HHS Secretary said Friday he anticipates having enough vaccine manufactured by the end of 2020 to vaccinate certain priority populations and enough to vaccinate all Americans by March to April 2021. Read More